



Clinical trial results:

An international multi-center, open-label study to evaluate safety, tolerability, biodistribution, dosimetry and preliminary efficacy of ¹⁷⁷Lu-OPS201 for the therapy of somatostatin receptor positive neuroendocrine tumours (NETs).

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2015-002867-41 |
| Trial protocol | AT GB DK |
| Global end of trial date | 22 February 2022 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 10 March 2023 |
| First version publication date | 10 March 2023 |

Trial information

Trial identification

| | |
|-----------------------|--------------------------|
| Sponsor protocol code | OPS-C-001/D-FR-01072-001 |
|-----------------------|--------------------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02592707 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Ipsen Pharma |
| Sponsor organisation address | 65, quai Georges Gorse, Boulogne Billancourt, France, 92100 |
| Public contact | Medical Director, Ipsen Pharma, clinical.trials@ipsen.com |
| Scientific contact | Medical Director, Ipsen Pharma, clinical.trials@ipsen.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 22 February 2022 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 22 February 2022 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

To assess the safety and tolerability of peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-OPS201 administered in 3 cycles in participants with somatostatin receptor (sstr) subtype 2-positive NETs (including pheochromocytomas and paragangliomas).

Protection of trial subjects:

The study was conducted under the provisions of the Declaration of Helsinki, in accordance with the International Conference on Harmonisation Consolidated Guideline on Good Clinical Practice and in compliance with Independent Ethics Committees/Institutional Review Boards and informed consent regulations.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 06 March 2017 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | Australia: 12 |
| Country: Number of subjects enrolled | Canada: 1 |
| Country: Number of subjects enrolled | Switzerland: 5 |
| Country: Number of subjects enrolled | United Kingdom: 5 |
| Country: Number of subjects enrolled | Austria: 2 |
| Country: Number of subjects enrolled | Denmark: 4 |
| Country: Number of subjects enrolled | France: 11 |
| Worldwide total number of subjects | 40 |
| EEA total number of subjects | 17 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|--|----|
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 23 |
| From 65 to 84 years | 17 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

This Phase 1/2, open-label study was conducted in participants with somatostatin receptor positive NETs at 8 investigational sites between 06 March 2017 and 22 February 2022. The sponsor terminated the study early for strategic reasons and this decision was not due to any safety or tolerability concern of the study drug.

Pre-assignment

Screening details:

This was 2-part study, Part A and B. Study consisted of a screening period (up to 4 weeks), treatment period (3 core treatment cycles in Part A and B; 2 additional cycles in Part B only: up to 30 months) and followed by long-term follow-up (LTFU) period (2 years). A total of 40 participants were treated.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--------|
| Are arms mutually exclusive? | Yes |
| Arm title | Part A |

Arm description:

Participants received 4.5 gigabecquerel (GBq) 177Lu-IPN01072 [target dose of 300 microgram (mcg) \pm 50 mcg] intravenous (IV) infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart [+2 weeks or up to +4 weeks in case of adverse events (AE) which had not adequately recovered].

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | 177Lu-IPN01072 |
| Investigational medicinal product code | |
| Other name | 177Lu-OPS201 |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

The study medication formulation consisted of 4.5 GBq of 177Lu-IPN01072 in a total volume of 20 milliliter (mL) that was administered by IV infusion over 120 minutes. The overall infusion duration did not exceeded 4 hours.

| | |
|------------------|------------------|
| Arm title | Cohort 1: Part B |
|------------------|------------------|

Arm description:

Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by data review board (DRB). As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | 177Lu-IPN01072 |
| Investigational medicinal product code | |
| Other name | 177Lu-OPS201 |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

The study medication formulation consisted of 6 GBq of 177Lu-IPN01072 in a total volume of 20 mL that was administered by IV infusion over 120 minutes. The overall infusion duration did not exceeded 4 hours.

| | |
|------------------|------------------|
| Arm title | Cohort 3: Part B |
|------------------|------------------|

Arm description:

Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | 177Lu-IPN01072 |
| Investigational medicinal product code | |
| Other name | 177Lu-OPS201 |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

The study medication formulation consisted of 4.5 GBq of 177Lu-IPN01072 in a total volume of 20 mL that was administered by IV infusion over 120 minutes. The overall infusion duration did not exceeded 4 hours.

| | |
|------------------|------------------|
| Arm title | Cohort 6: Part B |
|------------------|------------------|

Arm description:

Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | 177Lu-IPN01072 |
| Investigational medicinal product code | |
| Other name | 177Lu-OPS201 |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

The study medication formulation consisted of 4.5 GBq of 177Lu-IPN01072 in a total volume of 20 mL that was administered by IV infusion over 120 minutes. The overall infusion duration did not exceeded 4 hours.

| Number of subjects in period 1 | Part A | Cohort 1: Part B | Cohort 3: Part B |
|---------------------------------------|--------|------------------|------------------|
| Started | 15 | 6 | 9 |
| Completed | 9 | 1 | 3 |
| Not completed | 6 | 5 | 6 |
| Consent withdrawn by subject | - | 1 | 2 |
| Never entered LTFU period | 1 | - | - |
| Death | 1 | - | - |
| Progressive Disease | 4 | 4 | 3 |
| Unspecified | - | - | 1 |

| Number of subjects in period 1 | Cohort 6: Part B |
|---------------------------------------|------------------|
| Started | 10 |
| Completed | 3 |
| Not completed | 7 |
| Consent withdrawn by subject | - |
| Never entered LTFU period | 2 |

| | |
|---------------------|---|
| Death | - |
| Progressive Disease | 3 |
| Unspecified | 2 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|--------|
| Reporting group title | Part A |
|-----------------------|--------|

Reporting group description:

Participants received 4.5 gigabecquerel (GBq) 177Lu-IPN01072 [target dose of 300 microgram (mcg) \pm 50 mcg] intravenous (IV) infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart [+2 weeks or up to +4 weeks in case of adverse events (AE) which had not adequately recovered].

| | |
|-----------------------|------------------|
| Reporting group title | Cohort 1: Part B |
|-----------------------|------------------|

Reporting group description:

Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by data review board (DRB). As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|-----------------------|------------------|
| Reporting group title | Cohort 3: Part B |
|-----------------------|------------------|

Reporting group description:

Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|-----------------------|------------------|
| Reporting group title | Cohort 6: Part B |
|-----------------------|------------------|

Reporting group description:

Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| Reporting group values | Part A | Cohort 1: Part B | Cohort 3: Part B |
|--|------------|------------------|------------------|
| Number of subjects | 15 | 6 | 9 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 7 | 3 | 6 |
| From 65-84 years | 8 | 3 | 3 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 62.7 | 65.3 | 55.0 |
| standard deviation | \pm 12.9 | \pm 8.9 | \pm 16.0 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 8 | 2 | 3 |
| Male | 7 | 4 | 6 |

| | | | |
|---|----|---|---|
| Race | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 15 | 6 | 9 |
| Other | 0 | 0 | 0 |
| Ethnicity | | | |
| Units: Subjects | | | |
| Not Hispanic or Latino | 15 | 6 | 9 |

| Reporting group values | Cohort 6: Part B | Total | |
|--|------------------|-------|--|
| Number of subjects | 10 | 40 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 7 | 23 | |
| From 65-84 years | 3 | 17 | |
| 85 years and over | 0 | 0 | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 56.7 | | |
| standard deviation | ± 13.7 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 6 | 19 | |
| Male | 4 | 21 | |
| Race | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | |
| Asian | 0 | 0 | |
| Black or African American | 1 | 1 | |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | |
| White | 9 | 39 | |
| Other | 0 | 0 | |
| Ethnicity | | | |
| Units: Subjects | | | |
| Not Hispanic or Latino | 10 | 40 | |

End points

End points reporting groups

| | |
|-----------------------|--------|
| Reporting group title | Part A |
|-----------------------|--------|

Reporting group description:

Participants received 4.5 gigabecquerel (GBq) 177Lu-IPN01072 [target dose of 300 microgram (mcg) \pm 50 mcg] intravenous (IV) infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart [+2 weeks or up to +4 weeks in case of adverse events (AE) which had not adequately recovered].

| | |
|-----------------------|------------------|
| Reporting group title | Cohort 1: Part B |
|-----------------------|------------------|

Reporting group description:

Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by data review board (DRB). As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|-----------------------|------------------|
| Reporting group title | Cohort 3: Part B |
|-----------------------|------------------|

Reporting group description:

Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|-----------------------|------------------|
| Reporting group title | Cohort 6: Part B |
|-----------------------|------------------|

Reporting group description:

Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|----------------------------|------------------|
| Subject analysis set title | All Participants |
|----------------------------|------------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).

| | |
|----------------------------|--------------------------|
| Subject analysis set title | Part B: All Participants |
|----------------------------|--------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Sub-group analysis |
|---------------------------|--------------------|

Subject analysis set description:

Participants received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose from 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

| | |
|-----------------|--|
| End point title | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs ^[1] |
|-----------------|--|

End point description:

AE is defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product, which did not necessarily have a causal relationship with this treatment. A serious AE (SAE) was classified as any untoward medical occurrence that at any dose results in death; AE was life threatening; required inpatient hospitalization or prolonged existing hospitalization; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect; was an important medical event that may not result in death. TEAEs are defined as AEs that developed or worsened after start of treatment. The SAS included all participants who received 177Lu-IPN01072.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, maximum of 33 months.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical comparisons between the treatment groups was performed for safety endpoints.

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|-----------------------------|-----------------|------------------|------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 6 | 9 | 10 |
| Units: participants | | | | |
| number (not applicable) | | | | |
| TEAEs | 15 | 6 | 9 | 10 |
| Serious TEAEs | 2 | 1 | 2 | 3 |

| End point values | All Participants | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 40 | | | |
| Units: participants | | | | |
| number (not applicable) | | | | |
| TEAEs | 40 | | | |
| Serious TEAEs | 8 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Dose Limiting Toxicities (DLT)

| | |
|-----------------|---|
| End point title | Number of Participants With Dose Limiting Toxicities (DLT) ^[2] |
|-----------------|---|

End point description:

DLTs were defined as study medication-related AEs with a severity of Grade 3 or higher are considered DLT, with the exception of hair loss, lymphopenia, nonfebrile neutropenia lasting <4 weeks and thrombocytopenia lasting <4 weeks. The SAS included all participants who received 177Lu-IPN01072.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From the start of the first study medication (Cycle 1 Day 1) up to EOCT, maximum of 16 weeks.

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical comparisons between the treatment groups was performed for safety endpoints.

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|-----------------------------|-----------------|------------------|------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 6 | 9 | 10 |
| Units: participants | | | | |
| number (not applicable) | 3 | 0 | 2 | 1 |

| | | | | |
|-----------------------------|----------------------|--|--|--|
| End point values | All Participants | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 40 | | | |
| Units: participants | | | | |
| number (not applicable) | 6 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Uptake (%) of 177Lu-IPN01072 at Target Lesions and Discernible Organs in Cycle 1

| | |
|-----------------|--|
| End point title | Maximum Uptake (%) of 177Lu-IPN01072 at Target Lesions and Discernible Organs in Cycle 1 |
|-----------------|--|

End point description:

177Lu-IPN01072 uptake in organs and lesions was evaluated centrally, using nuclear medicine images, as part of the dosimetry workflow. Uptake activity for organs of interest (i.e., body, bone marrow, kidney (left + right), healthy liver, and spleen) was determined. The maximal uptake in lesions was calculated for each lesion as: maximal activity divided injected activity*100. The Per Protocol Dosimetry Analysis set (PP-DAS) included all participants in the Intent-To-Treat Dosimetry Analysis set (ITT-DAS) for whom no major protocol violations occurred affecting dosimetry variables. Only data from the participants analyzed were reported. 99999 indicates no participants were analyzed. Here, 'n' = number of participants analyzed at specific time point.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|--|---------------------------|--------------------------|---------------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 11 | 6 | 9 | 10 |
| Units: percentage of injected drug activity | | | | |
| median (full range (min-max)) | | | | |
| Bone marrow (image based) (n = 11, 6, 6, 6, 29) | 0.0469 (0.0246 to 0.0751) | 0.0420 (0.0100 to 0.280) | 0.0250 (0.0149 to 0.0570) | 0.0219 (0.0053 to 0.0300) |
| Liver (n = 7, 1, 0, 0, 8) | 1.52 (0.314 to 6.34) | 4.31 (4.31 to 4.31) | 99999 (99999 to 99999) | 99999 (99999 to 99999) |
| Kidney (left + right) (n = 11, 6, 9, 9, 35) | 1.96 (0.980 to 3.82) | 1.76 (1.05 to 2.08) | 1.60 (1.19 to 2.51) | 1.67 (0.749 to 2.41) |
| Spleen (n = 9, 6, 6, 6, 27) | 1.50 (0.274 to 2.93) | 1.27 (0.960 to 2.46) | 1.78 (0.550 to 5.97) | 1.79 (1.19 to 2.65) |
| All lesions (n = 11, 5, 9, 8, 33) | 0.651 (0.0290 to 6.35) | 2.36 (0.266 to 8.74) | 1.18 (0.235 to 18.7) | 1.43 (0.190 to 15.0) |

| End point values | All Participants | | | |
|--|--------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 36 | | | |
| Units: percentage of injected drug activity | | | | |
| median (full range (min-max)) | | | | |
| Bone marrow (image based) (n = 11, 6, 6, 6, 29) | 0.0380 (0.0053 to 0.280) | | | |
| Liver (n = 7, 1, 0, 0, 8) | 2.63 (0.314 to 6.34) | | | |
| Kidney (left + right) (n = 11, 6, 9, 9, 35) | 1.76 (0.749 to 3.82) | | | |
| Spleen (n = 9, 6, 6, 6, 27) | 1.67 (0.274 to 5.97) | | | |
| All lesions (n = 11, 5, 9, 8, 33) | 0.932 (0.0290 to 18.7) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Maximal Uptake (%) of 177Lu-IPN01072 of Blood in Cycle 1

| | |
|--|--|
| End point title | Maximal Uptake (%) of 177Lu-IPN01072 of Blood in Cycle 1 |
| End point description: 177Lu-IPN01072 uptake in blood was evaluated on site/locally using a gamma counter calibrated for 177Lu-IPN01072 according to the dosimetry operational manual. The radiopharmaceutical pharmacokinetic (PK) set included all participants in the ITT set who received at least 1 dose of study medication and had at least 1 measured radioactive concentration in blood. Only data from the participants analyzed were reported. | |
| End point type | Secondary |
| End point timeframe: Pre-infusion (Baseline), 5 and 30 minutes, 1, 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1 | |

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|-------------------------------|---------------------|---------------------|---------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 6 | 8 | 10 |
| Units: percentage/liter (L) | | | | |
| median (full range (min-max)) | 3.66 (2.17 to 7.88) | 2.98 (2.26 to 4.35) | 2.77 (1.98 to 7.35) | 3.32 (0.539 to 4.11) |

| End point values | All Participants | | | |
|------------------|------------------|--|--|--|
|------------------|------------------|--|--|--|

| | | | | |
|-------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 37 | | | |
| Units: percentage/liter (L) | | | | |
| median (full range (min-max)) | 3.03 (0.539 to 7.88) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Concentration Time Curve (AUC) of 177Lu-IPN01072 in Discernible Organs in Cycle 1

| | |
|---|--|
| End point title | Area Under the Concentration Time Curve (AUC) of 177Lu-IPN01072 in Discernible Organs in Cycle 1 |
| End point description: The AUC of 177Lu-IPN01072 radioactivity in discernible organs were computed for each administration of 177Lu-IPN01072. The PP-DAS included all participants in the ITT-DAS for whom no major protocol violations occurred affecting dosimetry variables. Only data from the participants analyzed were reported. 99999 indicates no participants were analyzed. Here, 'n' = number of participants analyzed at specific time point. | |
| End point type | Secondary |
| End point timeframe: 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1 | |

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|---|----------------------|------------------------|------------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 11 | 6 | 9 | 10 |
| Units: Megabecquerel (MBq)*hour | | | | |
| median (full range (min-max)) | | | | |
| Bone marrow (image based) (n = 11, 6, 6, 6, 29) | 174 (45.3 to 224) | 352 (154 to 3988) | 138 (91.0 to 362) | 157 (41.5 to 244) |
| Kidney (left + right) (n = 11, 6, 9, 9, 35) | 9596 (3896 to 26596) | 8966 (7350 to 10586) | 6239 (5853 to 11269) | 7578 (3320 to 9815) |
| Liver (n = 7, 1, 0, 0, 8) | 6745 (755 to 20751) | 17918 (17918 to 17918) | 99999 (99999 to 99999) | 99999 (99999 to 99999) |
| Spleen (n = 9, 6, 6, 6, 27) | 6701 (1134 to 21451) | 7949 (4945 to 11734) | 7727 (1547 to 28269) | 8179 (3901 to 12355) |

| End point values | All Participants | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 36 | | | |
| Units: Megabecquerel (MBq)*hour | | | | |
| median (full range (min-max)) | | | | |
| Bone marrow (image based) (n = 11, 6, 6, 6, 29) | 175 (41.5 to 3988) | | | |
| Kidney (left + right) (n = 11, 6, 9, 9, 35) | 8239 (3320 to 26596) | | | |

| | | | | |
|-----------------------------|----------------------|--|--|--|
| Liver (n = 7, 1, 0, 0, 8) | 11133 (755 to 20751) | | | |
| Spleen (n = 9, 6, 6, 6, 27) | 7772 (1134 to 28269) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: AUC of 177Lu-IPN01072 in Blood in Cycle 1

| | |
|--|---|
| End point title | AUC of 177Lu-IPN01072 in Blood in Cycle 1 |
| End point description: The AUC of 177Lu-IPN01072 radioactivity in blood were computed for each administration of 177Lu-IPN01072. The radiopharmaceutical PK set included all participants in the ITT set who received at least 1 dose of study medication and had at least 1 measured radioactive concentration in blood. Only data from the participants analyzed were reported. | |
| End point type | Secondary |
| End point timeframe: Pre-infusion (Baseline), 5 and 30 minutes, 1, 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1 | |

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|-------------------------------|-------------------|-------------------|-------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 6 | 8 | 10 |
| Units: MBq*hour/L | | | | |
| median (full range (min-max)) | 623 (299 to 1003) | 901 (442 to 1806) | 690 (371 to 1201) | 720 (290 to 1034) |

| End point values | All Participants | | | |
|-------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 37 | | | |
| Units: MBq*hour/L | | | | |
| median (full range (min-max)) | 726 (290 to 1806) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Terminal Half-Life (T1/2) of Radioactivity Concentrations of the Radiopharmaceutical in Blood in Cycle 1

| | |
|-----------------|--|
| End point title | Terminal Half-Life (T1/2) of Radioactivity Concentrations of the Radiopharmaceutical in Blood in Cycle 1 |
|-----------------|--|

End point description:

The terminal half-life was defined as the largest half-life of the decay curve of blood activity. The radiopharmaceutical PK set included all participants in the ITT set who received at least 1 dose of study medication and had at least 1 measured radioactive concentration in blood. Only data from the participants analyzed were reported.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-infusion (Baseline), 5 and 30 minutes, 1, 4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|-------------------------------|--------------------|-------------------|-------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 6 | 8 | 10 |
| Units: hours | | | | |
| median (full range (min-max)) | 68.3 (42.2 to 160) | 109 (38.6 to 160) | 123 (41.2 to 160) | 145 (55.3 to 160) |

| End point values | All Participants | | | |
|-------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 37 | | | |
| Units: hours | | | | |
| median (full range (min-max)) | 127 (38.6 to 160) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Highest Absorbed Dose of 177LU-OPS201 to Each Discernible Organ in Cycle 1

| | |
|-----------------|--|
| End point title | Highest Absorbed Dose of 177LU-OPS201 to Each Discernible Organ in Cycle 1 |
|-----------------|--|

End point description:

The absorbed dose to the discernible organs (i.e., organs showing uptake) was evaluated centrally, using nuclear medicine images, as part of the dosimetry workflow. The organs considered for 177LU-OPS201 image-based dosimetry assessment included: liver, bone marrow, kidney (left + right), and spleen. The PP-DAS included all participants in the ITT-DAS for whom no major protocol violations occurred affecting dosimetry variables.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

4, 24, 48, 72 to 96 and 144 to 168 hours post infusion in Cycle 1

| End point values | All Participants | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 36 | | | |
| Units: Gray | | | | |
| number (not applicable) | | | | |
| Bone (image-based assay) | 3.59 | | | |
| Kidney (left + right) | 8.07 | | | |
| Liver | 1.26 | | | |
| Spleen | 8.07 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Specific Absorbed Dose Per Organ and Lesions of 177Lu-IPN01072 in Cycle 1

| | |
|-----------------|---|
| End point title | Specific Absorbed Dose Per Organ and Lesions of 177Lu-IPN01072 in Cycle 1 |
|-----------------|---|

End point description:

The specific absorbed dose was evaluated centrally, using nuclear medicine images, as part of the dosimetry workflow. Data are presented for all lesions, regardless of their anatomical localization. The organs considered for 177LUOPS201 image-based dosimetry assessment included: liver, bone marrow, kidney (left + right), and spleen. The PP-DAS included all participants in the ITT-DAS for whom no major protocol violations occurred affecting dosimetry variables. Only data from the participants analyzed were reported. 99999 indicates no participants were analyzed. Here, 'n' = number of participants analyzed at specific time point.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycle 1

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|---|--------------------------|-------------------------|--------------------------|--------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 11 | 6 | 9 | 10 |
| Units: Gray/GBq | | | | |
| median (full range (min-max)) | | | | |
| Lesions (n = 11, 5, 9, 8, 33) | 2.56 (0.431 to 14.3) | 3.90 (1.92 to 83.3) | 6.82 (2.07 to 28.2) | 13.5 (2.20 to 81.0) |
| Bone marrow (image based) (n = 11, 6, 6, 6, 29) | 0.0796 (0.0431 to 0.216) | 0.135 (0.0900 to 0.610) | 0.0850 (0.0700 to 0.110) | 0.0650 (0.0100 to 0.150) |
| Kidney (left + right) (n = 11, 6, 9, 9, 35) | 1.05 (0.522 to 1.85) | 0.720 (0.600 to 1.02) | 0.880 (0.460 to 1.18) | 0.765 (0.420 to 1.10) |
| Liver (n = 7, 1, 0, 0, 8) | 0.186 (0.146 to 0.279) | 0.170 (0.170 to 0.170) | 99999 (99999 to 99999) | 99999 (99999 to 99999) |
| Spleen (n = 9, 6, 6, 6, 27) | 0.769 (0.208 to 1.79) | 0.945 (0.500 to 1.08) | 0.985 (0.180 to 1.46) | 0.805 (0.360 to 0.980) |

| End point values | All Participants | | | |
|---|--------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 36 | | | |
| Units: Gray/GBq | | | | |
| median (full range (min-max)) | | | | |
| Lesions (n = 11, 5, 9, 8, 33) | 5.00 (0.431 to 83.3) | | | |
| Bone marrow (image based) (n = 11, 6, 6, 6, 29) | 0.0900 (0.0100 to 0.610) | | | |
| Kidney (left + right) (n = 11, 6, 9, 9, 35) | 0.879 (0.420 to 1.85) | | | |
| Liver (n = 7, 1, 0, 0, 8) | 0.179 (0.146 to 0.279) | | | |
| Spleen (n = 9, 6, 6, 6, 27) | 0.840 (0.180 to 1.79) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cumulative Absorbed Organ Doses of 177Lu-IPN01072 in Cycles 1 and 3

| | |
|-----------------|---|
| End point title | Cumulative Absorbed Organ Doses of 177Lu-IPN01072 in Cycles 1 and 3 |
|-----------------|---|

End point description:

The cumulative absorbed dose in the discernible organs (i.e., organs showing uptake) was evaluated centrally, using nuclear medicine images, as part of the dosimetry workflow. The PP-DAS included all participants in the ITT-DAS for whom no major protocol violations occurred affecting dosimetry variables. Only data from the participants analyzed were reported. 99999 indicates no participants were analyzed. Cycle (C). Here, 'n' = number of participants analyzed at specific time point.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

4, 24, 48, 72 to 96 hours, 144 to 168 hours post infusion in Cycles 1 and 3

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|--|------------------------|------------------------|------------------------|-------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 11 | 6 | 9 | 10 |
| Units: Gray | | | | |
| median (full range (min-max)) | | | | |
| C1:Bone marrow (image based) (n = 11, 6, 6, 6, 29) | 0.319 (0.102 to 0.974) | 0.715 (0.390 to 3.59) | 0.375 (0.260 to 0.500) | 0.285 (0.0400 to 0.690) |
| C1:Kidney (left + right) (n = 11, 6, 9, 9, 35) | 4.31 (2.17 to 8.07) | 3.85 (3.36 to 4.58) | 3.25 (1.79 to 5.34) | 3.55 (1.74 to 4.88) |
| C1:Liver (n = 7, 1, 0, 0, 8) | 0.720 (0.336 to 1.26) | 0.810 (0.810 to 0.810) | 99999 (99999 to 99999) | 99999 (99999 to 99999) |
| C1:Spleen (n = 9, 6, 6, 6, 27) | 2.88 (0.844 to 8.07) | 4.35 (3.17 to 6.00) | 4.00 (0.710 to 5.90) | 3.55 (1.48 to 4.09) |
| C3:Bone marrow (image based) (n = 11, 1, 6, 3, 21) | 1.11 (0.636 to 2.17) | 1.48 (1.48 to 1.48) | 1.09 (0.830 to 1.24) | 0.840 (0.290 to 1.23) |
| C3:Kidney (left + right) (n = 11, 1, 8, 5, 25) | 12.3 (7.67 to 24.1) | 9.41 (9.41 to 9.41) | 8.91 (6.29 to 14.0) | 10.1 (6.95 to 11.5) |

| | | | | |
|--------------------------------|---------------------|------------------------|------------------------|------------------------|
| C3:Liver (n = 7, 0, 0, 0, 7) | 2.08 (1.01 to 4.14) | 99999 (99999 to 99999) | 99999 (99999 to 99999) | 99999 (99999 to 99999) |
| C3:Spleen (n = 9, 1, 5, 3, 18) | 6.93 (4.99 to 15.6) | 7.58 (7.58 to 7.58) | 9.21 (2.82 to 14.6) | 8.08 (5.66 to 14.2) |

| End point values | All Participants | | | |
|--|------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 36 | | | |
| Units: Gray | | | | |
| median (full range (min-max)) | | | | |
| C1:Bone marrow (image based) (n = 11, 6, 6, 6, 29) | 0.400 (0.4000 to 3.59) | | | |
| C1:Kidney (left + right) (n = 11, 6, 9, 9, 35) | 3.73 (1.74 to 8.07) | | | |
| C1:Liver (n = 7, 1, 0, 0, 8) | 0.765 (0.336 to 1.26) | | | |
| C1:Spleen (n = 9, 6, 6, 6, 27) | 3.45 (0.710 to 8.07) | | | |
| C3:Bone marrow (image based) (n = 11, 1, 6, 3, 21) | 1.10 (0.290 to 2.17) | | | |
| C3:Kidney (left + right) (n = 11, 1, 8, 5, 25) | 10.8 (6.29 to 24.1) | | | |
| C3:Liver (n = 7, 0, 0, 0, 7) | 2.08 (1.01 to 4.14) | | | |
| C3:Spleen (n = 9, 1, 5, 3, 18) | 8.32 (2.82 to 15.6) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cumulative Amount of Lu-177 Radioactivity Excreted Into the Urine (0 to 48 Hours) [Ae (0-48h)] in Cycle 1

| | |
|-----------------|---|
| End point title | Cumulative Amount of Lu-177 Radioactivity Excreted Into the Urine (0 to 48 Hours) [Ae (0-48h)] in Cycle 1 |
|-----------------|---|

End point description:

Urine was collected during the first 48 hours post infusion to determine the renal excretion of ¹⁷⁷Lu-IPN01072 at Cycle 1 only. The Radiopharmaceutical PK set (Part A and Part B) included all participants in the ITT set who received at least 1 dose of study medication and had at least 1 measured radioactive concentration in blood.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

0 to 6 hours, 6 to 24 hours, 24 to 48 hours post-infusion in Cycle 1 of Part A; 0 to 4 hours, 4 to 24 hours, 24 to 48 hours in Cycle 1 of Part B.

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|-------------------------------|---------------------|---------------------|---------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 6 | 8 | 9 |
| Units: Mbq | | | | |
| median (full range (min-max)) | 2586 (1722 to 4450) | 3106 (2558 to 3998) | 2640 (1346 to 3375) | 2621 (471 to 3181) |

| End point values | All Participants | | | |
|-------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 36 | | | |
| Units: Mbq | | | | |
| median (full range (min-max)) | 2787 (471 to 4450) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Reach Maximum Plasma Concentration (Tmax) of IPN01072 in Cycle 1

| | |
|-----------------|--|
| End point title | Time to Reach Maximum Plasma Concentration (Tmax) of IPN01072 in Cycle 1 |
|-----------------|--|

End point description:

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only. The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

| End point values | Part B: All Participants | | | |
|-------------------------------|--------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: hours | | | | |
| median (full range (min-max)) | 0.083 (0.00 to 0.28) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Plasma Concentration (C_{max}) of IPN01072 in Cycle 1

| | |
|-----------------|--|
| End point title | Maximum Observed Plasma Concentration (C _{max}) of IPN01072 in Cycle 1 |
|-----------------|--|

End point description:

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only. The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

| End point values | Part B: All Participants | | | |
|--------------------------------------|--------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: nanogram (ng)/milliliter (mL) | | | | |
| arithmetic mean (standard deviation) | 10.7 (± 5.47) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: AUC From Time Zero to Infinity (AUC_{inf}) of IPN01072 in Cycle 1

| | |
|-----------------|---|
| End point title | AUC From Time Zero to Infinity (AUC _{inf}) of IPN01072 in Cycle 1 |
|-----------------|---|

End point description:

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only. The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

| | | | | |
|--------------------------------------|--------------------------|--|--|--|
| End point values | Part B: All Participants | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: ng*hour (h)/mL | | | | |
| arithmetic mean (standard deviation) | 45.8 (± 20.6) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: T1/2 of IPN01072 in Cycle 1

| | |
|-----------------|-----------------------------|
| End point title | T1/2 of IPN01072 in Cycle 1 |
|-----------------|-----------------------------|

End point description:

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only. The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

| | | | | |
|--------------------------------------|--------------------------|--|--|--|
| End point values | Part B: All Participants | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: hours | | | | |
| arithmetic mean (standard deviation) | 6.09 (± 1.59) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Apparent Total Plasma Clearance of IPN01072 (Total CL) in Cycle 1

| | |
|-----------------|---|
| End point title | Apparent Total Plasma Clearance of IPN01072 (Total CL) in Cycle 1 |
|-----------------|---|

End point description:

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only. The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

| End point values | Part B: All Participants | | | |
|--------------------------------------|--------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: L/h | | | | |
| arithmetic mean (standard deviation) | 9.58 (\pm 12.8) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Apparent Volume of Distribution During Terminal Phase (V_z) of IPN01072 in Cycle 1

| | |
|-----------------|--|
| End point title | Apparent Volume of Distribution During Terminal Phase (V _z) of IPN01072 in Cycle 1 |
|-----------------|--|

End point description:

The PK sampling was performed from Day 1 to Day 3 post infusion done at Cycle 1 for Part B only. The IPN01072 PK set in plasma (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and have no major protocol deviations affecting the plasma PK variables and who had a sufficient number of plasma levels to estimate the main PK parameters. Only data from the participants analyzed were reported.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-infusion (Baseline) and 5 minutes, 30 minutes, 60 minutes, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours after the end of the infusion in Cycle 1

| End point values | Part B: All Participants | | | |
|--------------------------------------|--------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: Liter | | | | |
| arithmetic mean (standard deviation) | 68.7 (\pm 52.0) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Ae (0-48h) of IPN01072 in Cycle 1

| | |
|-----------------|-----------------------------------|
| End point title | Ae (0-48h) of IPN01072 in Cycle 1 |
|-----------------|-----------------------------------|

End point description:

Urine was collected during the first 48 hours post infusion to determine the renal excretion of ¹⁷⁷Lu-IPN01072 at Cycle 1 for Part B only. The IPN01072 PK set in urine (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and had no major protocol deviations

affecting the urine PK variables and who had all urine IPN01072 levels available to estimate the main urine PK parameters.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

0 to 4 hours, 4 to 24 hours, 24 to 48 hours in Cycle 1 of Part B

| End point values | Part B: All Participants | | | |
|--------------------------------------|--------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 23 | | | |
| Units: mcg | | | | |
| arithmetic mean (standard deviation) | 141 (± 65.9) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Fraction of IPN01072 Excreted Into the Urine (Fe) in Cycle 1

| | |
|-----------------|--|
| End point title | Fraction of IPN01072 Excreted Into the Urine (Fe) in Cycle 1 |
|-----------------|--|

End point description:

Urine was collected during the first 48 hours post infusion to determine the renal excretion of ¹⁷⁷Lu-IPN01072 at Cycle 1 for Part B only. The IPN01072 PK set in urine (Part B only) included all participants in the ITT set who received at least 1 dose of study medication and had no major protocol deviations affecting the urine PK variables and who had all urine IPN01072 levels available to estimate the main urine PK parameters.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

0 to 4 hours, 4 to 24 hours, 24 to 48 hours in Cycle 1 in Part B

| End point values | Part B: All Participants | | | |
|---|--------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 23 | | | |
| Units: percentage of drug excreted into urine | | | | |
| arithmetic mean (standard deviation) | 52.9 (± 24.2) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Response Rate (ORR)

| | |
|-----------------|-----------------------------|
| End point title | Overall Response Rate (ORR) |
|-----------------|-----------------------------|

End point description:

The ORR was defined as the percentage of participants who achieved a complete response (CRs) or a partial response (PR) as best overall response (BOR) according centralized to response evaluation criteria in solid tumours (RECIST) version 1.1 from investigator assessment. Participants with no tumour assessment after the start of study treatment were not evaluated. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The ITT included all participants in the eligible participants set who received study medication.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the start of the first study medication (Cycle 1 Day 1) up to 2 years after the EOCT/death or lost to follow-up, maximum of 59 months.

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|-----------------------------------|---------------------|--------------------|--------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 6 | 9 | 10 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 40.0 (16.3 to 67.7) | 16.7 (0.4 to 64.1) | 22.2 (2.8 to 60.0) | 40.0 (12.2 to 73.8) |

| End point values | All Participants | | | |
|-----------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 40 | | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 32.5 (18.6 to 49.1) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Disease Control Rate (DCR)

| | |
|-----------------|----------------------------|
| End point title | Disease Control Rate (DCR) |
|-----------------|----------------------------|

End point description:

The DCR was defined as the percentage of participants who achieved a CR, a PR or a stable disease (SD) as BOR according to Investigator assessment RECIST version 1.1 criteria. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. The ITT included all participants in the eligible participants set who received study medication.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the start of the first study medication (Cycle 1 Day 1) up to 2 years after the EOCT/death or lost to follow-up, maximum of 59 months.

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|-----------------------------------|---------------------|-----------------------|-----------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 6 | 9 | 10 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 93.3 (68.1 to 99.8) | 100.0 (54.1 to 100.0) | 100.0 (66.4 to 100.0) | 90.0 (55.5 to 99.7) |

| End point values | All Participants | | | |
|-----------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 40 | | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 95.0 (83.1 to 99.4) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Best Overall Response

| | |
|-----------------|-----------------------|
| End point title | Best Overall Response |
|-----------------|-----------------------|

End point description:

The BOR according to RECIST v1.1 was defined as the best response recorded from the initiation of treatment until the EOCT/end of additional cycles (EOAC)/early withdrawal (EW) Visit (during the core study part), prior to the Investigator assessment of progressive disease (PD). Progression was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm.

The ITT included all participants in the eligible participants set who received study medication.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the start of the first study medication (Cycle 1 Day 1) up to 2 years after the EOCT/death or lost to follow-up, maximum of 59 months.

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 6 | 9 | 10 |
| Units: count of participants | | | | |
| number (not applicable) | | | | |
| PR | 6 | 1 | 2 | 4 |
| SD | 8 | 5 | 7 | 5 |

| | | | | |
|--------------------|---|---|---|---|
| PD | 1 | 0 | 0 | 0 |
| Not Evaluable (NE) | 0 | 0 | 0 | 1 |

| | | | | |
|------------------------------|----------------------|--|--|--|
| End point values | All Participants | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 40 | | | |
| Units: count of participants | | | | |
| number (not applicable) | | | | |
| PR | 13 | | | |
| SD | 25 | | | |
| PD | 1 | | | |
| Not Evaluable (NE) | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Progression Free Survival (PFS)

| | |
|---|---------------------------------|
| End point title | Progression Free Survival (PFS) |
| End point description: | |
| The PFS was defined as the time from start of study treatment until occurrence of tumour progression or death, according to Investigator assessment RECIST version 1.1. Estimation of the median was based on the Kaplan-Meier method. The ITT included all participants in the eligible participants set who received study medication. 99999 indicates upper limit of CI are non-estimable. | |
| End point type | Secondary |
| End point timeframe: | |
| From the start of the first study medication (Cycle 1 Day 1) up to 2 years after the EOCT/death or lost to follow-up, maximum of 59 months. | |

| | | | | |
|----------------------------------|----------------------|---------------------|---------------------|---------------------|
| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 6 | 3 | 6 | 5 |
| Units: months | | | | |
| median (confidence interval 95%) | 29.7 (17.5 to 99999) | 21.2 (19.4 to 22.4) | 25.1 (5.1 to 99999) | 11.1 (5.1 to 99999) |

| | | | | |
|----------------------------------|----------------------|--|--|--|
| End point values | All Participants | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 20 | | | |
| Units: months | | | | |
| median (confidence interval 95%) | 28.1 (20.0 to 99999) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Quality of Life (QoL) Questionnaire (QLQ)-C30 at EOCT Visit

| | |
|--|---|
| End point title | Change From Baseline in Quality of Life (QoL) Questionnaire (QLQ)-C30 at EOCT Visit |
| End point description: | |
| <p>The European Organisation for Research and Treatment of Cancer (EORTC) score QLQ-C30 was used for QoL evaluation. Each scale in the questionnaire was scored (0 to 100) according to the EORTC recommendations in the EORTC QLQ-C30 scoring manual. The scale included a global health status, where high score for the global health status represents a high QoL. The functional scales consisted of physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, where a higher value reflected a better level of function. 9 symptoms scales included nausea and vomiting, pain, fatigue, dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties, where a higher value reflected worse symptoms. The ITT set. Only data from the participants analyzed were reported. 99999 indicates that standard deviation could not be calculated as only 1 participant was analyzed.</p> | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline (Day 1) and EOCT visit (30 months) | |

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|--------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 1 | 8 | 4 |
| Units: score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Global Health Status | 1.27 (± 23.54) | 16.70 (± 99999) | -6.24 (± 14.61) | 29.15 (± 28.43) |
| Physical functioning | -2.05 (± 11.03) | 0.00 (± 99999) | -0.82 (± 6.61) | 10.00 (± 20.00) |
| Role functioning | 3.85 (± 29.79) | 0.00 (± 99999) | -0.01 (± 19.90) | 12.50 (± 25.00) |
| Emotional functioning | 11.52 (± 30.15) | -25.00 (± 99999) | -4.16 (± 7.74) | 10.43 (± 12.51) |
| Cognitive functioning | 6.41 (± 19.89) | 0.00 (± 99999) | -6.26 (± 12.43) | 12.50 (± 15.95) |
| Social functioning | 15.38 (± 33.65) | 0.00 (± 99999) | -2.09 (± 5.90) | 12.50 (± 25.00) |

| End point values | All Participants | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 26 | | | |

| | | | | |
|--------------------------------------|----------------|--|--|--|
| Units: score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Global Health Status | 3.84 (± 23.83) | | | |
| Physical functioning | 0.26 (± 11.70) | | | |
| Role functioning | 3.85 (± 25.08) | | | |
| Emotional functioning | 5.12 (± 23.70) | | | |
| Cognitive functioning | 3.20 (± 17.66) | | | |
| Social functioning | 8.97 (± 26.35) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in QLQ Gastro-intestinal. Neuroendocrine Tumour (GI.NET)21 at EOCT Visit

| | |
|-----------------|---|
| End point title | Change From Baseline in QLQ Gastro-intestinal. Neuroendocrine Tumour (GI.NET)21 at EOCT Visit |
|-----------------|---|

End point description:

The GI.NET21 module was intended for use among participants with gastrointestinal related (GI.-related) neuroendocrine tumours, who vary in disease stage and treatments. The module comprises 21 questions, consisting of 5 scales (endocrine symptoms, G.I. symptoms, treatment related symptom, social function, disease related worries) and 4 single items that assessed muscle /bone pain symptom, sexual function, information/communication function, and body image. Each question was quoted from 1 (not at all) to 4 (very much). Each scale was scored from 0 to 100. A higher value was equivalent to worse or more problems. Baseline was defined as the last non-missing measurement collected prior to the first dose of study drug (Day 1). The ITT included all participants in the eligible participants set who received study medication. Only data from the participants analyzed were reported. 99999 indicates that standard deviation could not be calculated as only 1 participant was analyzed.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and EOCT visit (30 months)

| End point values | Part A | Cohort 1: Part B | Cohort 3: Part B | Cohort 6: Part B |
|--------------------------------------|------------------|------------------|------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 1 | 8 | 4 |
| Units: score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Endocrine symptoms | -5.12 (± 13.31) | 11.10 (± 99999) | -0.00 (± 5.93) | -5.55 (± 11.10) |
| G. I. symptoms | -3.58 (± 13.49) | -6.70 (± 99999) | 2.50 (± 7.04) | -13.30 (± 17.22) |
| Treatment related symptom | 5.62 (± 21.47) | -6.70 (± 99999) | 9.01 (± 15.11) | -0.30 (± 8.15) |
| Social function | -19.67 (± 15.83) | -22.30 (± 99999) | -4.15 (± 8.29) | -30.53 (± 5.55) |
| Disease related worries | -8.98 (± 14.63) | -22.20 (± 99999) | 3.46 (± 16.53) | -18.05 (± 13.87) |

| End point values | All Participants | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 26 | | | |
| Units: score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Endocrine symptoms | -2.98 (± 11.13) | | | |
| G. I. symptoms | -3.33 (± 12.81) | | | |
| Treatment related symptom | 5.28 (± 17.56) | | | |
| Social function | -16.67 (± 15.17) | | | |
| Disease related worries | -7.06 (± 16.37) | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the start of the first study medication (Cycle 1 Day 1) up to 6 months after the last dose of study medication, maximum of 33 months. Adverse events beyond 6 months after the last dose were not presented.

Adverse event reporting additional description:

The SAS included all participants who received study medication. Participants who received the therapeutic dose of 177Lu-IPN01072 during the core trial period in Part A and B.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 23.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--------------------------------|
| Reporting group title | Part A: 177Lu-IPN01072 4.5 GBq |
|-----------------------|--------------------------------|

Reporting group description:

Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg \pm 50 mcg) IV infusion on Day 1 of 3 treatment cycles. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).

| | |
|-----------------------|---------------------------------------|
| Reporting group title | Part B Cohort 1: 177Lu-IPN01072 6 GBq |
|-----------------------|---------------------------------------|

Reporting group description:

Participants received 6 GBq 177Lu-IPN01072 (target dose of 300 mcg) IV infusion on Day 1 of 3 treatment cycles. The radioactivity dose was reduced to 4.5 GBq in Cohort 1 adapted as recommended by DRB. As a result, Cohort 1 adapted was similar to Cohort 1 except the radioactivity dose was 4.5 GBq. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|-----------------------|---|
| Reporting group title | Part B Cohort 3: 177Lu-IPN01072 4.5 GBq |
|-----------------------|---|

Reporting group description:

Participants received 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 700 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|-----------------------|---|
| Reporting group title | Part B Cohort 6: 177Lu-IPN01072 4.5 GBq |
|-----------------------|---|

Reporting group description:

Participants received of 4.5 GBq 177Lu-IPN01072 (target dose of 300 mcg in Cycle 1; 1300 mcg in Cycle 2; 300 mcg in Cycle 3) IV infusion on Day 1 of 3 treatment cycles. Target dose was 300 mcg for additional cycles, if any. Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AEs which had not adequately recovered).

| | |
|-----------------------|------------------|
| Reporting group title | All Participants |
|-----------------------|------------------|

Reporting group description:

Participants who received 177Lu-IPN01072 dose from 4.5 to 6 GBq (target dose of 300 to 1300 mcg) as IV infusion on Day 1 of 3 treatment cycles/additional 2 cycles (when applicable). Each cycle was 8 weeks apart (+2 weeks or up to +4 weeks in case of AE which had not adequately recovered).

| Serious adverse events | Part A: 177Lu-IPN01072 4.5 GBq | Part B Cohort 1: 177Lu-IPN01072 6 GBq | Part B Cohort 3: 177Lu-IPN01072 4.5 GBq |
|---|--------------------------------|---------------------------------------|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 1 / 6 (16.67%) | 2 / 9 (22.22%) |
| number of deaths (all causes) | 2 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| | | | |
|---|----------------|----------------|----------------|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acute myeloid leukaemia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Precursor B-lymphoblastic lymphoma | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 1 / 6 (16.67%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Tumour marker increased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Hypotension | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |

| | | | |
|--|----------------|----------------|----------------|
| Presyncope | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 1 / 6 (16.67%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 3 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |

| | | | |
|--|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|---|------------------|--|
| Serious adverse events | Part B Cohort 6: 177Lu-IPN01072 4.5 GBq | All Participants | |
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 3 / 10 (30.00%) | 8 / 40 (20.00%) | |
| number of deaths (all causes) | 1 | 3 | |
| number of deaths resulting from adverse events | 1 | 1 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acute myeloid leukaemia | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 1 / 2 | 1 / 2 | |
| deaths causally related to treatment / all | 1 / 1 | 1 / 1 | |
| Malignant melanoma | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Precursor B-lymphoblastic lymphoma | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Tumour marker increased | | | |

| | | | |
|--|-----------------|----------------|--|
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Hypotension | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Tachycardia | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Presyncope | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyrexia | | | |

| | | | |
|---|-----------------|----------------|--|
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 0 | 3 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Back pain | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| Non-serious adverse events | Part A: 177Lu-IPN01072 4.5 GBq | Part B Cohort 1: 177Lu-IPN01072 6 GBq | Part B Cohort 3: 177Lu-IPN01072 4.5 GBq |
|---|---------------------------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 15 / 15 (100.00%) | 6 / 6 (100.00%) | 9 / 9 (100.00%) |
| Vascular disorders | | | |
| Flushing | | | |
| subjects affected / exposed | 9 / 15 (60.00%) | 0 / 6 (0.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 13 | 0 | 5 |
| Hot flush | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypotension | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 2 | 0 | 5 |
| Hypertension | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 1 | 0 | 1 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 3 / 15 (20.00%) | 3 / 6 (50.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 3 | 3 | 5 |
| Fatigue | | | |
| subjects affected / exposed | 9 / 15 (60.00%) | 0 / 6 (0.00%) | 3 / 9 (33.33%) |
| occurrences (all) | 13 | 0 | 6 |
| Feeling hot | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Infusion site reaction | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 2 / 6 (33.33%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 5 |
| Chest pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Injection site bruising | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Injection site swelling | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sense of oppression | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--|--|--|---|
| Xerosis subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Reproductive system and breast disorders Ovarian cyst subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Dyspnoea subjects affected / exposed occurrences (all) Epistaxis subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all) Wheezing subjects affected / exposed occurrences (all) Dyspnoea exertional subjects affected / exposed occurrences (all) Hiccups subjects affected / exposed occurrences (all) Lung cyst subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 1 / 15 (6.67%) 1 2 / 15 (13.33%) 2 1 / 15 (6.67%) 1 1 / 15 (6.67%) 1 0 / 15 (0.00%) 0 0 / 15 (0.00%) 0 0 / 15 (0.00%) 0 | 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 1 / 9 (11.11%) 3 0 / 9 (0.00%) 0 1 / 9 (11.11%) 1 0 / 9 (0.00%) 0 1 / 9 (11.11%) 1 0 / 9 (0.00%) 0 0 / 9 (0.00%) 0 |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 1 / 9 (11.11%) 1 |

| | | | |
|--|----------------------|---------------------|----------------------|
| Affective disorder subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 9 (0.00%) 0 |
| Depressed mood subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Sleep disorder subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Product issues Product leakage subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Investigations Lymphocyte count decreased subjects affected / exposed occurrences (all) | 3 / 15 (20.00%) 8 | 0 / 6 (0.00%) 0 | 4 / 9 (44.44%) 14 |
| Platelet count decreased subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 2 | 0 / 6 (0.00%) 0 | 4 / 9 (44.44%) 11 |
| White blood cell count decreased subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 5 | 0 / 6 (0.00%) 0 | 2 / 9 (22.22%) 6 |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 1 / 9 (11.11%) 2 |
| Blood urea increased subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 2 | 0 / 6 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Protein urine present subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 1 / 9 (11.11%) 4 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Albumin urine present | | | |

| | | | |
|---------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood potassium decreased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood potassium increased | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Blood pressure decreased | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cardiac murmur | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cortisol decreased | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Creatinine renal clearance decreased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Electrocardiogram ambulatory abnormal | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 2 |

| | | | |
|--|----------------------|---------------------|---------------------|
| Liver function test increased subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 2 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Bilirubin urine present subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 9 (11.11%) 2 |
| Injury, poisoning and procedural complications | | | |
| Infusion related reaction subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 3 | 1 / 6 (16.67%) 1 | 0 / 9 (0.00%) 0 |
| Fall subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Burn oesophageal subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Contusion subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Muscle strain subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 9 (0.00%) 0 |
| Occupational exposure to radiation subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Cardiac disorders | | | |
| Tachycardia subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 3 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Supraventricular extrasystoles subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 0 / 6 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Arrhythmia | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 5 / 15 (33.33%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 7 | 0 | 3 |
| Dizziness | | | |
| subjects affected / exposed | 4 / 15 (26.67%) | 1 / 6 (16.67%) | 1 / 9 (11.11%) |
| occurrences (all) | 5 | 1 | 1 |
| Dysgeusia | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 0 / 6 (0.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 4 | 0 | 2 |
| Lethargy | | | |
| subjects affected / exposed | 3 / 15 (20.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 8 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 1 | 0 | 1 |
| Parosmia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 0 | 0 | 2 |
| Syncope | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 1 / 6 (16.67%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Hypogeusia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Sensory disturbance | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|--------------------------------------|-----------------|----------------|----------------|
| Blood and lymphatic system disorders | | | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 3 / 15 (20.00%) | 3 / 6 (50.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 10 | 13 | 4 |
| Neutropenia | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 2 / 6 (33.33%) | 1 / 9 (11.11%) |
| occurrences (all) | 3 | 6 | 1 |
| Anaemia | | | |
| subjects affected / exposed | 3 / 15 (20.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 3 | 0 | 1 |
| Lymphopenia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 2 / 6 (33.33%) | 2 / 9 (22.22%) |
| occurrences (all) | 1 | 10 | 2 |
| Leukopenia | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 1 / 6 (16.67%) | 1 / 9 (11.11%) |
| occurrences (all) | 2 | 4 | 1 |
| Lymph node pain | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myelosuppression | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Deafness neurosensory | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Deafness unilateral | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| External ear pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vestibular disorder | | | |

| | | | |
|--|---------------------|--------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Nausea | | | |
| subjects affected / exposed | 12 / 15 (80.00%) | 1 / 6 (16.67%) | 5 / 9 (55.56%) |
| occurrences (all) | 24 | 1 | 13 |
| Diarrhoea | | | |
| subjects affected / exposed | 8 / 15 (53.33%) | 1 / 6 (16.67%) | 6 / 9 (66.67%) |
| occurrences (all) | 18 | 1 | 14 |
| Vomiting | | | |
| subjects affected / exposed | 5 / 15 (33.33%) | 0 / 6 (0.00%) | 4 / 9 (44.44%) |
| occurrences (all) | 8 | 0 | 12 |
| Abdominal pain | | | |
| subjects affected / exposed | 5 / 15 (33.33%) | 1 / 6 (16.67%) | 1 / 9 (11.11%) |
| occurrences (all) | 7 | 1 | 2 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 5 / 15 (33.33%) | 1 / 6 (16.67%) | 0 / 9 (0.00%) |
| occurrences (all) | 5 | 1 | 0 |
| Constipation | | | |
| subjects affected / exposed | 4 / 15 (26.67%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 4 | 0 | 1 |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 1 / 6 (16.67%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Gastrointestinal sounds abnormal | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Abdominal discomfort | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 1 | 0 | 1 |

| | | | |
|------------------------------------|----------------|----------------|----------------|
| Abdominal distension | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dry mouth | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 1 | 0 | 1 |
| Stomatitis | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 1 / 6 (16.67%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Abnormal faeces | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Anorectal discomfort | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Breath odour | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dental caries | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Frequent bowel movements | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastrointestinal motility disorder | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Gingival bleeding | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---|-----------------------|---------------------|---------------------|
| Lip dry subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Odynophagia subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Paraesthesia oral subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 9 (0.00%) 0 |
| Steatorrhoea subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 2 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Toothache subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Hepatobiliary disorders | | | |
| Hepatomegaly subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 3 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Hepatic pain subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia subjects affected / exposed occurrences (all) | 9 / 15 (60.00%) 14 | 2 / 6 (33.33%) 2 | 3 / 9 (33.33%) 3 |
| Dry skin subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 3 | 1 / 6 (16.67%) 1 | 0 / 9 (0.00%) 0 |
| Rash subjects affected / exposed occurrences (all) | 1 / 15 (6.67%) 1 | 1 / 6 (16.67%) 1 | 1 / 9 (11.11%) 2 |
| Hyperhidrosis subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 6 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Pruritus | | | |

| | | | |
|---|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 1 | 0 | 1 |
| Erythema | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash papular | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 1 / 6 (16.67%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Renal and urinary disorders | | | |
| Microalbuminuria | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 3 / 15 (20.00%) | 1 / 6 (16.67%) | 2 / 9 (22.22%) |
| occurrences (all) | 5 | 1 | 5 |
| Back pain | | | |
| subjects affected / exposed | 5 / 15 (33.33%) | 0 / 6 (0.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 6 | 0 | 3 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 1 / 6 (16.67%) | 0 / 9 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Groin pain | | | |

| | | | |
|--------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 1 | 0 | 1 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 1 | 0 | 1 |
| Bone pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 2 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spinal pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infections and infestations | | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 3 / 15 (20.00%) | 1 / 6 (16.67%) | 2 / 9 (22.22%) |
| occurrences (all) | 3 | 1 | 2 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|----------------|----------------|----------------|
| Sinusitis | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 1 / 6 (16.67%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Anal fungal infection | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Conjunctivitis | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Groin abscess | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Perineal infection | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 1 / 6 (16.67%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |

| | | | |
|-----------------------------|-----------------|---------------|---------------|
| subjects affected / exposed | 2 / 15 (13.33%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Increased appetite | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 6 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| Non-serious adverse events | Part B Cohort 6: 177Lu-IPN01072 4.5 GBq | All Participants | |
|---|--|------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 9 / 10 (90.00%) | 39 / 40 (97.50%) | |
| Vascular disorders | | | |
| Flushing | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 12 / 40 (30.00%) | |
| occurrences (all) | 3 | 21 | |
| Hot flush | | | |
| subjects affected / exposed | 3 / 10 (30.00%) | 4 / 40 (10.00%) | |
| occurrences (all) | 3 | 4 | |
| Hypotension | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 3 / 40 (7.50%) | |
| occurrences (all) | 0 | 7 | |
| Hypertension | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 0 | 2 | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 5 / 10 (50.00%) | 13 / 40 (32.50%) | |
| occurrences (all) | 11 | 22 | |
| Fatigue | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 13 / 40 (32.50%) | |
| occurrences (all) | 1 | 20 | |
| Feeling hot | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 0 | 2 | |
| Infusion site reaction | | | |

| | | |
|-----------------------------|-----------------|----------------|
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 2 |
| Malaise | | |
| subjects affected / exposed | 2 / 10 (20.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 3 | 3 |
| Pyrexia | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 2 |
| Chest discomfort | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 5 |
| Chest pain | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Chills | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 1 | 1 |
| Discomfort | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 1 | 1 |
| Influenza like illness | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Injection site bruising | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Injection site reaction | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Injection site swelling | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Non-cardiac chest pain | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Oedema peripheral | | |

| | | | |
|---|-----------------|----------------|--|
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Pain | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Sense of oppression | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 1 | 1 | |
| Xerosis | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 2 | 2 | |
| Reproductive system and breast disorders | | | |
| Ovarian cyst | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 1 | 1 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 3 / 40 (7.50%) | |
| occurrences (all) | 1 | 3 | |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 3 / 40 (7.50%) | |
| occurrences (all) | 1 | 5 | |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 0 | 2 | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 0 | 2 | |
| Wheezing | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 1 | 2 | |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Hiccups | | | |

| | | | |
|--|----------------------|-----------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 1 / 40 (2.50%) 1 | |
| Lung cyst subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 1 / 40 (2.50%) 1 | |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 2 / 40 (5.00%) 2 | |
| Affective disorder subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Depressed mood subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Sleep disorder subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Product issues Product leakage subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Investigations Lymphocyte count decreased subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 7 / 40 (17.50%) 22 | |
| Platelet count decreased subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 5 / 40 (12.50%) 13 | |
| White blood cell count decreased subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 4 / 40 (10.00%) 11 | |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 2 | 3 / 40 (7.50%) 5 | |
| Blood urea increased | | | |

| | | |
|--------------------------------------|----------------|----------------|
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 3 |
| Protein urine present | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 5 |
| White blood cell count increased | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 2 |
| Albumin urine present | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Blood alkaline phosphatase increased | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Blood creatinine increased | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 2 |
| Blood potassium decreased | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Blood potassium increased | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 3 |
| Blood pressure decreased | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Cardiac murmur | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Cortisol decreased | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Creatinine renal clearance decreased | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Electrocardiogram QT prolonged | | |

| | | | |
|--|----------------|----------------|--|
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Electrocardiogram ambulatory abnormal | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 2 | |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 2 | |
| Bilirubin urine present | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 2 | |
| Injury, poisoning and procedural complications | | | |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 3 / 40 (7.50%) | |
| occurrences (all) | 0 | 4 | |
| Fall | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 0 | 2 | |
| Burn oesophageal | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Contusion | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Occupational exposure to radiation | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Cardiac disorders | | | |

| | | | |
|--------------------------------|-----------------|-----------------|--|
| Tachycardia | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 3 / 40 (7.50%) | |
| occurrences (all) | 2 | 5 | |
| Palpitations | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 1 | 2 | |
| Supraventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 0 | 2 | |
| Arrhythmia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 1 | 2 | |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 7 / 40 (17.50%) | |
| occurrences (all) | 1 | 11 | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 6 / 40 (15.00%) | |
| occurrences (all) | 0 | 7 | |
| Dysgeusia | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 5 / 40 (12.50%) | |
| occurrences (all) | 3 | 9 | |
| Lethargy | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 3 / 40 (7.50%) | |
| occurrences (all) | 0 | 8 | |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 0 | 2 | |
| Parosmia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) | |
| occurrences (all) | 0 | 2 | |
| Syncope | | | |

| | | | |
|---|----------------------|-----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Taste disorder subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 2 / 40 (5.00%) 4 | |
| Hypogeusia subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 2 | |
| Sensory disturbance subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Blood and lymphatic system disorders | | | |
| Thrombocytopenia subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 8 / 40 (20.00%) 28 | |
| Neutropenia subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 3 | 6 / 40 (15.00%) 13 | |
| Anaemia subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 2 | 5 / 40 (12.50%) 6 | |
| Lymphopenia subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 5 / 40 (12.50%) 13 | |
| Leukopenia subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 4 / 40 (10.00%) 7 | |
| Lymph node pain subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 1 / 40 (2.50%) 1 | |
| Myelosuppression subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 1 / 40 (2.50%) 1 | |
| Ear and labyrinth disorders Deafness neurosensory | | | |

| | | | |
|-----------------------------|-----------------|------------------|--|
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 1 | 1 | |
| Deafness unilateral | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 1 | 1 | |
| External ear pain | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Vestibular disorder | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 1 | 1 | |
| Gastrointestinal disorders | | | |
| Nausea | | | |
| subjects affected / exposed | 8 / 10 (80.00%) | 26 / 40 (65.00%) | |
| occurrences (all) | 15 | 53 | |
| Diarrhoea | | | |
| subjects affected / exposed | 6 / 10 (60.00%) | 21 / 40 (52.50%) | |
| occurrences (all) | 8 | 41 | |
| Vomiting | | | |
| subjects affected / exposed | 6 / 10 (60.00%) | 15 / 40 (37.50%) | |
| occurrences (all) | 9 | 29 | |
| Abdominal pain | | | |
| subjects affected / exposed | 3 / 10 (30.00%) | 10 / 40 (25.00%) | |
| occurrences (all) | 4 | 14 | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 2 / 10 (20.00%) | 8 / 40 (20.00%) | |
| occurrences (all) | 5 | 11 | |
| Constipation | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 6 / 40 (15.00%) | |
| occurrences (all) | 1 | 6 | |
| Dyspepsia | | | |
| subjects affected / exposed | 2 / 10 (20.00%) | 4 / 40 (10.00%) | |
| occurrences (all) | 2 | 4 | |

| | | |
|----------------------------------|-----------------|----------------|
| Flatulence | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 3 / 40 (7.50%) |
| occurrences (all) | 1 | 3 |
| Gastrointestinal sounds abnormal | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 3 / 40 (7.50%) |
| occurrences (all) | 1 | 3 |
| Gastrooesophageal reflux disease | | |
| subjects affected / exposed | 2 / 10 (20.00%) | 3 / 40 (7.50%) |
| occurrences (all) | 3 | 4 |
| Abdominal discomfort | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 2 |
| Abdominal distension | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 1 | 2 |
| Dry mouth | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 2 |
| Stomatitis | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 2 |
| Abdominal pain lower | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Abnormal faeces | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Anorectal discomfort | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |
| Breath odour | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 1 | 1 |
| Dental caries | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 1 |

| | | | |
|---|----------------------|---------------------|--|
| Epigastric discomfort subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Frequent bowel movements subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Gastrointestinal motility disorder subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 2 | |
| Gingival bleeding subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Lip dry subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 1 / 40 (2.50%) 1 | |
| Odynophagia subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 1 / 40 (2.50%) 1 | |
| Paraesthesia oral subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Steatorrhoea subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 2 | |
| Toothache subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 1 / 40 (2.50%) 1 | |
| Hepatobiliary disorders Hepatomegaly subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 2 / 40 (5.00%) 3 | |
| Hepatic pain subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|-----------------|------------------|--|
| Alopecia | | | |
| subjects affected / exposed | 5 / 10 (50.00%) | 19 / 40 (47.50%) | |
| occurrences (all) | 5 | 24 | |
| Dry skin | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 4 / 40 (10.00%) | |
| occurrences (all) | 1 | 5 | |
| Rash | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 4 / 40 (10.00%) | |
| occurrences (all) | 1 | 5 | |
| Hyperhidrosis | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 3 / 40 (7.50%) | |
| occurrences (all) | 1 | 3 | |
| Pruritus | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 3 / 40 (7.50%) | |
| occurrences (all) | 1 | 3 | |
| Erythema | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Night sweats | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 1 | 1 | |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Rash papular | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Urticaria | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 0 | 1 | |
| Renal and urinary disorders | | | |
| Microalbuminuria | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) | |
| occurrences (all) | 1 | 1 | |
| Musculoskeletal and connective tissue disorders | | | |

| | | |
|--------------------------------|-----------------|-----------------|
| Arthralgia | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 7 / 40 (17.50%) |
| occurrences (all) | 2 | 13 |
| Back pain | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 7 / 40 (17.50%) |
| occurrences (all) | 0 | 9 |
| Musculoskeletal chest pain | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 3 / 40 (7.50%) |
| occurrences (all) | 0 | 3 |
| Arthritis | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 2 |
| Groin pain | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 2 |
| Musculoskeletal pain | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 4 |
| Pain in extremity | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 2 / 40 (5.00%) |
| occurrences (all) | 0 | 2 |
| Bone pain | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 3 |
| Coccydynia | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 2 |
| Intervertebral disc protrusion | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 1 | 1 |
| Musculoskeletal stiffness | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 0 | 2 |
| Myalgia | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 40 (2.50%) |
| occurrences (all) | 4 | 4 |

| | | | |
|---|----------------------|----------------------|--|
| Spinal pain subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Infections and infestations | | | |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 7 / 40 (17.50%) 7 | |
| Bronchitis subjects affected / exposed occurrences (all) | 2 / 10 (20.00%) 2 | 2 / 40 (5.00%) 2 | |
| Gastroenteritis subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 2 / 40 (5.00%) 2 | |
| Sinusitis subjects affected / exposed occurrences (all) | 2 / 10 (20.00%) 2 | 2 / 40 (5.00%) 2 | |
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 2 / 40 (5.00%) 2 | |
| Anal fungal infection subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Conjunctivitis subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Cystitis subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 1 / 40 (2.50%) 1 | |
| Groin abscess subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Perineal infection subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 1 / 40 (2.50%) 1 | |
| Pharyngitis | | | |

| | | | |
|---|----------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 1 / 40 (2.50%) 1 | |
| Tooth abscess subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Tooth infection subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Viral upper respiratory tract infection subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite subjects affected / exposed occurrences (all) | 3 / 10 (30.00%) 3 | 5 / 40 (12.50%) 6 | |
| Hyperglycaemia subjects affected / exposed occurrences (all) | 1 / 10 (10.00%) 1 | 2 / 40 (5.00%) 2 | |
| Increased appetite subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 1 / 40 (2.50%) 1 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 16 October 2015 | The protocol was amended to address feedback from different authorities and ethics committees. The protocol was also adapted according to standard procedures of the new owner, IPSEN Pharma. Changes included clarifications to inclusion and exclusion, adaptation of the activity escalation scheme to allow greater freedom to the Safety Review Board, removal of an exploratory evaluation of the somatostatin receptor scan, addition of computed tomography/magnetic resonance imaging at Week 12 after the first peptide receptor radionuclide therapy cycle, shifting the EOCT Visit from Week 28 to Week 24 and a number of administrative changes. |
| 02 December 2015 | The protocol was amended since the initially selected CRO Syneed Medidata was replaced as it entered an insolvency procedure and the sponsor did not want to take the risk of its bankruptcy during the conduct of the trial. The responsibility for pharmacovigilance and safety reporting was assumed by the sponsor leading to changes which were administrative in nature. |
| 11 December 2015 | The protocol was amended to specify that specific tumour and pituitary markers will be analysed in a central laboratory since some clinical sites do not have all these assessments in the repertoire of the local laboratory. |
| 29 April 2016 | The protocol was amended to consistently state that in the event of pregnancy the participant 'will' be withdrawn from treatment. |
| 04 October 2016 | The study population was updated. Exploratory objectives added. Several additional safety measures were included. Changes updated to figure 8, 9, 10 and 11. Changes updated to Table 5. Change in sponsor name, study administration section, sponsor approval signatory page and minor typographical changes for consistency throughout the protocol. |
| 03 November 2017 | Sponsor name updated, project coordinator and sponsor representative name corrected. Editorial changes applied. Extended screening period from 3 to 4 weeks. Confirmed the targeted radioactivity, confirmed that serum pregnancy test was to be done at Screening visit only. Clarification about pituitary markers. Entry criteria clarified. All changes listed above did not interfere with primary endpoint of the study and were done for clarification and to facilitate the recruitment and logistics for the participants and centers. |

| | |
|------------------|---|
| 27 February 2018 | <p>Editorial changes made in order to put the protocol into the Ipsen template. Peptide mass dose escalation was added to Part B of the study with a design in two cohorts to evaluate if somatostatin receptor subtype 2 receptor saturation is occurring. The design in these two cohorts is a test-retest of increasing peptide at the second cycle to evaluate if receptor saturation is occurring. To carry out additional dose escalation of both peptide mass and radioactivity, eight cohorts have been developed with a step wise increase of peptide mass and radioactivity. The total number of participants in Part B increased. For Part B: Inclusion criteria modified and an exclusion criterion added; Additional changes applied to all participants from the time of implementation. Assessment of urine PK of IPN01072; Evaluation of systemic immune response and circulating markers added; Additional computed tomography (CT)/ magnetic resonance imaging and single-photon emission CT/CT scans added; Dosimetry assessments performed in additional cycles; Rules for delayed administration and treatment withdrawal changed; The list of conditions which were resolved was expanded. Change in tumor volume assessment added. Assessment of deoxyribonucleic acid double strand breaks in lymphocytes and tumour growth rate were removed. Tumour markers and PK parameters assessed were specified. The infusion rates and duration were revised. The volume of blood taken overall were updated. The urine collection time for dosimetric measurements were updated. Schedule of biopsy material collection specified. Details on action taken in case of spillage of investigational radiopharmaceutical product added. Participant withdrawal criteria specified. AE criteria specified. The introduction and study objectives updated.</p> |
| 24 July 2018 | <p>The protocol was amended to update the screening criteria (refining the inclusion and exclusion criteria) and contact details for the pharmacovigilance and coordinating investigator, to add precautions for handling radioactive material, to add a new assessment day (around Day 42) at which haematology and biochemistry were to be assessed and to make clarifications and corrections for consistency. Changes to clarify the interruption of somatostatin analogue therapy and criteria and safety monitoring that must be met for administering additional cycle were requested by the Food and Drug Administration.</p> |
| 07 May 2019 | <p>The protocol was amended to update personnel (sponsor's representative and signatory), the infusion time/rate and other infusion-related procedures, to amend various assessments timings and clarify inclusion in the additional optional cycles, to amend dose escalation rules in case of toxicity, to specify urine sample collections in US and Canada sites, to amend AE/SAE reporting requirements, including in cases of laboratory abnormalities, to add definition and procedures for adverse event of special interest, to correct minor errors and make other clarifications.</p> |
| 13 August 2019 | <p>The protocol was amended to update the planned study period, to add an exploratory objective and endpoints to determine therapeutic efficacy using the modified RECIST , to clarify secondary endpoint related to tumour response, to clarify aspects related to the additional cycles (4 and 5) and amend their image reading to be done by a central laboratory, to define DLT definition in Part B, to clarify reporting procedures in "special situation" events, to clarify the decision process for administration of the additional cycles, to add AE reporting for IPN60070, to amend timing of assessments in Part B, to add screened participants population, to add interim analyses such that a total of three were to be performed and aid with cohort initiation decision, to correct minor errors and make other clarifications.</p> |

| | |
|----------------|--|
| 10 August 2020 | The protocol was amended to clarify the 2-year long-term follow-up period. To add details of the option for participants to take part in a safety surveillance study after the long-term follow-up period is completed. To add an analysis of the 177Lu-IPN01072 dosimetry results according to the formula of the amino-acid solution administrated. To align the tumour response secondary endpoints (ORR, BOR, and DCR) with the statistical analysis plan. To change the secondary objective and secondary endpoint of changes in tumour volume to an exploratory objective and exploratory endpoint. To add DoR as an exploratory endpoint to further characterize the tumour response. To clarify the study populations (Safety Analysis set and ITT set) for analysis. To clarify the timing of the interim analyses and the clinical study report preparation. To clarify about coronavirus disease 2019 following the recent pandemic. To remove reference to the master protocol on the title page as, due to a change in the development strategy, the master protocol Ipsen 001 Version 1.0 has been closed. To align the synopsis and main body of the protocol for consistency. To correct minor errors and make other clarifications. |
|----------------|--|

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to strategic reasons, the Ipsen management team decided to early terminate the D-FR-01072-001 / OPS-C-001 study. This decision was not due to any safety or tolerability concern, or any event associated with the use of the study drug.

Notes: